These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17652924)

  • 21. First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses.
    Spencer K; Cowans NJ; Avgidou K; Molina F; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jan; 31(1):15-9. PubMed ID: 17999381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intraoperator and interoperator repeatability of manual and semi-automated measurement of increased fetal nuchal translucency according to the operator's experience.
    Kagan KO; Abele H; Yazdi B; Böer B; Pintoffl K; Wright D; Hoopmann M
    Prenat Diagn; 2011 Dec; 31(13):1229-33. PubMed ID: 22024964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Nicolaides' risk evaluation for Down's syndrome with a novel software: an analysis of 1,463 cases.
    Schmidt P; Staboulidou I; Soergel P; Wüstemann M; Hillemanns P; Scharf A
    Arch Gynecol Obstet; 2007 Jun; 275(6):469-74. PubMed ID: 17333228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The prenatal detection of trisomy 13, 18, and 21: comparison of the advanced first trimester screening (AFS) with the first trimester screening according to Nicolaides].
    Hörmansdörfer C; Schmidt P; Hillemanns P; Scharf A
    Z Geburtshilfe Neonatol; 2007 Dec; 211(6):243-9. PubMed ID: 18176905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new approach to calculating the risk of chromosomal abnormalities with first-trimester screening data.
    Merz E; Thode C; Alkier A; Eiben B; Hackelöer BJ; Hansmann M; Huesgen G; Kozlowski P; Pruggmaier M; Wellek S
    Ultraschall Med; 2008 Dec; 29(6):639-45. PubMed ID: 19085755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nuchal translucency and first-trimester screening.
    Harry WG; Reed KL
    J Soc Gynecol Investig; 2006 Apr; 13(3):153-4. PubMed ID: 16638584
    [No Abstract]   [Full Text] [Related]  

  • 27. Impact of nuchal translucency credentialing by the FMF, the NTQR or both on screening distributions and performance.
    Evans MI; Krantz DA; Hallahan TW; Sherwin J
    Ultrasound Obstet Gynecol; 2012 Feb; 39(2):181-4. PubMed ID: 21484907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-trimester and second-trimester screening at a community hospital: experience from the first year of implementation.
    Philipson EH; Callahan M; Jelovsek JE
    Obstet Gynecol; 2008 Aug; 112(2 Pt 1):218-22. PubMed ID: 18669714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-trimester combined screening for Down syndrome: prediction of low birth weight, small for gestational age and pre-term delivery in a cohort of non-selected women.
    Pihl K; Sørensen TL; Nørgaard-Pedersen B; Larsen SO; Nguyen TH; Krebs L; Larsen T; Christiansen M
    Prenat Diagn; 2008 Mar; 28(3):247-53. PubMed ID: 18302310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery.
    Spencer K; Cowans NJ; Molina F; Kagan KO; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Feb; 31(2):147-52. PubMed ID: 17992705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contingent screening for Down syndrome--results from the FaSTER trial.
    Cuckle HS; Malone FD; Wright D; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Ferreira JC; Dugoff L; Craigo SD; Timor IE; Carr SR; Wolfe HM; D'Alton ME
    Prenat Diagn; 2008 Feb; 28(2):89-94. PubMed ID: 18236423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Valencia C; Maiz N; Nicolaides KH
    Hum Reprod; 2008 Sep; 23(9):1968-75. PubMed ID: 18544579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Three-dimensional scatter plot analysis to estimate the risk of foetal aneuloidy].
    Schmidt P; Hörmansdörfer C; Oehler K; Härtel H; Hillemanns P; Scharf A
    Z Geburtshilfe Neonatol; 2008 Aug; 212(4):127-35. PubMed ID: 18729035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First trimester ultrasonography in screening and detection of fetal anomalies.
    Sonek J
    Am J Med Genet C Semin Med Genet; 2007 Feb; 145C(1):45-61. PubMed ID: 17304542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should the first-trimester aneuploidy screen be maternal age adjusted? Screening by absolute risk versus risk adjusted to maternal age.
    Gebb J; Dar P
    Prenat Diagn; 2009 Mar; 29(3):245-7. PubMed ID: 19248042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Women's opinions on the offer and use of nuchal translucency screening for Down syndrome.
    Müller MA; Bleker OP; Bonsel GJ; Bilardo CM
    Prenat Diagn; 2006 Feb; 26(2):105-11. PubMed ID: 16463289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation.
    Kagan KO; Anderson JM; Anwandter G; Neksasova K; Nicolaides KH
    Prenat Diagn; 2008 Dec; 28(13):1209-13. PubMed ID: 19039823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Practitioner-specific medians for nuchal translucency to improve first-trimester screening performance.
    Wu N; Platt LD; Greene N; Currier RJ
    Obstet Gynecol; 2012 Apr; 119(4):785-94. PubMed ID: 22433342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How imprecise may the measurement of fetal nuchal translucency be without worsening first-trimester screening?
    Schmidt P; Staboulidou I; Elsässer M; Vaske B; Hillemanns P; Scharf A
    Fetal Diagn Ther; 2008; 24(3):291-5. PubMed ID: 18818502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance of first-trimester combined screening for trisomy 13 and 18 with the double test taken at a gestational age of 8 + 0 to 13 + 6.
    Kirkegaard I; Petersen OB; Uldbjerg N; Tørring N
    Prenat Diagn; 2009 Jun; 29(6):582-7. PubMed ID: 19288457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.